Mathew Blackman
Stock Analyst at Stifel
(1.47)
# 1492
Out of 5,329 analysts
66
Total ratings
51.61%
Success rate
10.06%
Average return
Main Sectors:
Top Industries:
| Name | Action | PT | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
TNDM Tandem Diabetes Care | Maintains: Buy | 60 31 | 19.99 | 55.08% | 6 | May 1, 2025 | |
PEN Penumbra | Maintains: Strong Buy | 301 318 | 291.69 | 9.02% | 2 | Apr 24, 2025 | |
CLPT ClearPoint Neuro | Maintains: Strong Buy | 19 25 | 13.93 | 79.47% | 3 | Apr 1, 2025 | |
BBNX Beta Bionics | Initiates Coverage On: Buy | 25 | 11.14 | 124.42% | 1 | Feb 24, 2025 | |
PODD Insulet | Maintains: Hold | 245 293 | 250.38 | 17.02% | 3 | Feb 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Strong Buy | 92 94 | 71.08 | 32.25% | 5 | Feb 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Buy | 18 24 | 13.59 | 76.6% | 5 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 6 3 | 1.3 | 130.77% | 1 | Oct 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Hold | 50 | n/a | n/a | 1 | Sep 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Strong Buy | 90 100 | 70.19 | 42.47% | 11 | Aug 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 19 16 | 11.13 | 43.76% | 5 | Aug 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Hold | 6 7 | 7.06 | -0.85% | 11 | May 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Hold | 18 11 | 8.52 | 29.11% | 4 | May 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Hold | 10 | n/a | n/a | 3 | Jan 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 18 16 | n/a | n/a | 2 | Mar 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 64 | n/a | n/a | 1 | Oct 20, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Hold | 30 | n/a | n/a | 2 | Aug 26, 2020 |